Fortunately, studies have shown that patients with elevated CRP levels can have their cardiovascular risk lowered by statin therapy. Notably, a landmark clinical trial called JUPITER (Justification of the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) studied apparently healthy people with average LDL levels, but elevated hsCRP. When their LDL cholesterol and hsCRP levels were treated to extremely low levels with aggressive statin therapy, their risk of heart attack, stroke and cardiac death was decreased by almost 80 percent. Achieving very low LDL levels proved to be more important than achieving very low LDL levels. This implies that inflammation, as indicated by hsCRP, is a risk factor for the development of artherosclerosis even when cholesterol levels are low.
To read more important news and information about your hearts health, purchase the special report from Cleveland Clinics Heart Advisor, Coronary Artery Disease, Advanced in Detection and Treatment.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!